Dalton Pharma Services has added Flow Chemistry reactor technology to its services offering. This new technology expands capabilities in the area of custom synthesis and process development and offers increased scalability, flexibility, and process control.
 
“Adding flow chemistry technology keeps us on the leading edge of the chemistry business, and builds on three decades of experience and innovation in custom chemical synthesis,” said Peter Pekos, chief executive officer and president of Dalton Pharma Services.  “Our clients need more efficient and scalable approaches to custom synthesis which enable safe cost management and environmental responsibility.  By being able to seamlessly transfer the chemical process to our cGMP API manufacturing suites, clients can accelerate their drug development programs.”
 
Dalton has initiated work with small scale reactions up to several hundred grams and will continue to expand the scale of its Flow Chemistry capabilities in API process development and custom synthesis.

Visit Dalton at Table 108